Teva Shoots For Top Three In Pain And Respiratory
Teva’s new management has homed in on pain and respiratory disease as two core therapeutic areas. During the firm’s second quarter earnings call, CEO Erez Vigodman gave a sneak peek at his comprehensive portfolio review.
You may also be interested in...
Fate of migraine patch remains uncertian after 'large number' of patients suffer burns and scars; adverse event was issue during review of transdermal sumatriptan product, but didn't even make it into labeling; nine months later the problems have forced Teva to suspend marketing.
Teva’s recent restricting has the firm focusing internal R&D on CNS and respiratory therapies, with plans to out-license or creatively finance development of non-core pipeline assets.
The company will focus its R&D resources on central nervous system disorders and respiratory disease, but will end investment in women’s health and oncology.